AbstractÐConjugates of bisphosphonates (potential bone resorption inhibitors) and prostaglandin E 2 (a bone formation enhancer) were prepared and evaluated for their ability to bind to bone and to liberate, enzymatically, free PGE 2 . The conjugate 3, an amide at C-1 of PGE 2 proved to be too stable in vivo while conjugate 6, a thioester, was too labile. Several PGE 2 , C-15 ester-linked conjugates (18, 23, 24 and 31) were prepared and conjugate 23 was found to bind eectively to bone in vitro and in vivo and to liberate PGE 2 at an acceptable rate. A 4-week study in a rat model of osteoporosis showed that 23 was better tolerated and more eective as a bone growth stimulant than daily maximum tolerated doses of free PGE 2 . #
Introduction
Osteoporosis is the most common metabolic bone disease which aects 40±50% of the elderly female and 10±15% of the elderly male population. 1 The disease involves the gradual loss of bone mass as a result of an imbalance between the bone resorption activity of osteoclasts and the bone formation activity of osteoblasts. 2 A number of pharmaceutical agents have been developed to treat this disease. These compounds can be divided into two groups: bone resorption inhibitors such as bisphosphonates 3 (e.g. Fosamax
1
) and bone formation stimulants. 4±8 Bisphosphonates are analogues of pyrophosphates which are absorbed tightly onto hydroxyapitite surfaces and, due to this process, bisphosphonates are targetted to bone. 9 While bisphosphonates represent an important class of drugs for the treatment of osteoporosis, their value is generally manifested by prevention of bone loss and thus, for treatment of more advanced disease, there has been great interest in the discovery of safe and eective bone formation stimulants. Examples of bone-activating agents may include parathyroid hormone, 4 growth hormone, 5¯u oride, 6 possibly certain vitamin D metabolites 7 and prostaglandin E 2 (PGE 2 ). 8 Indeed, a number of studies have demonstrated that bone formation can be stimulated in vivo by systemic injection of PGE 2 . 10 Furthermore, substantial new bone formation has been observed on the controlled release of PGE 2 from implanted PGE 2 -containing polymers 11 indicating that PGE 2 acts locally in bone. Unfortunately, such implants are impractical in a normal therapeutic setting and the pharmaceutical utility of systemic PGE 2 is greatly reduced due to side eects and metabolic instability.
Conjugates of PGE 2 and bisphosphonates described in this report represent a new class of compounds which could circumvent the problems associated with PGE 2 . PGE 2 (or an analogue) chemically coupled to a bisphosphonate could be eectively delivered to bone due to the property of the bisphosphonate to bind to bone. Gradual hydrolysis of the conjugate could then liberate a bone resorption inhibitor (the bisphosphonate moiety) and a bone formation enhancer (the PGE 2 moiety). To test this hypothesis, it was necessary to devise methods to couple bisphosphonates and PGE 2 in a way compatible with the chemical and biochemical instability of PGE 2 through a linkage which was suitably stable for the conjugate to survive intact during the time necessary for uptake into bone in vivo, and suitably labile to be subsequently released by metabolic hydrolysis. Ideally, a hydrolytic half-life of 1 to 4 days was sought. In order to monitor eectively both the uptake and release of the prostaglandin moiety in the bone, it was decided to utilize radioactive-labelled PGE 2 . In early experiments, we also utilized radioactive-labelled bisphosphonate and thus double label analysis of plasma and bone samples over time could be used to follow the uptake and cleavage of the conjugate. Finally, when conjugates with appropriate properties were discovered, more complex in vivo experiments to measure their eect on bone formation were undertaken.
Results and Discussion
Synthesis and studies of conjugates linked via the C-1 carboxyl group of PGE 2 12 Synthesis of PGE 2 -alendronate conjugate 3. With the commercial availability of tritium-labelled PGE 2 (1) and the in-house availability of 14 C-labelled alendronate (2), we ®rst explored the direct coupling of alendrolate with PGE 2 to provide the corresponding amide (3). The Nhydroxysuccinimide ester of PGE 2 was readily prepared using DCC as coupling agent and the active ester reacted eciently with alendronate in dioxane±water with careful control of the pH at 8±9 in order to ensure the integrity of the PGE 2 (higher pH led to competing elimination of the 11-hydroxyl group to the corresponding enone) (Scheme 1). Puri®cation of the conjugate was dicult but could be achieved ®rst by evaporation to dryness and then dissolution of the mixture in water and absorption onto a C18 cartridge followed by elution ®rst with water and then with acetonitrile±water to provide fractions that were essentially pure conjugate 3. In this manner, quantities both of unlabelled and double-labelled conjugate 3 could be prepared.
In vitro and in vivo evaluation of conjugate 3. The conjugate 3 was studied ®rst in vitro to determine its binding to bone powder. These experiments showed that irreversible in vitro binding of 3 in fetal bovine serum (FBS) to bone powder occurred to the extent of 77% of the 14 C moiety (alendronate) and 53% of the 3 H moiety (PGE 2 ) within 1 h. Thereafter, disassociation of the PGE 2 moiety could be followed during incubation with FBS by measuring the residual 14 C/ 3 H ratio. These experiments indicated that disassociation of the 3 H moiety occurred at the rate of approximately 5% per day at 37 C. Conjugate 3 was then studied for its ability to be taken up in the bone in vivo and the subsequent liberation of PGE 2 as measured by 3 H loss from bone over time. An initial indication of the eect on bone degradation/formation was also obtained by measure of the release of lysylpyridinolenes (LP) over time. A high level of urinary LP is normally associated with the accelerated breakdown of bone collagen. 13 For the in vivo experiments, rats were dosed i.v. with a single dose of dual-labelled compound 3 and then animals were sacri®ced at 24 h, 14 and 28 days after administration. The level of 14 C/ 3 H was measured after an incineration of the long bones. These studies indicated about 15% of 14 C and 12% of 3 H associated with conjugate 3 were taken up at 24 h compared with about 33% for 3 Halendronate itself. At 14 and 28 days, there was no signi®cant change in the ratio of 14 C to 3 H, indicating the stability of the conjugate in situ (Fig. 1) . A statistically signi®cant reduction of LP was observed on day 12 for animals treated with the conjugate, although not as great as was observed for the alendronate itself dosed at 1 mg/kg (see Fig. 2 ). The results of these experiments suggested that hydrolysis of the amide was inecient in vivo and thus an alternative, more labile coupling methodology was sought.
Synthesis of PGE 2 -thioester-alendronate conjugate 6. It was felt that a thioester would be signi®cantly more labile and perhaps more suitable. The synthesis of such a conjugate was complicated by the instability of PGE 2 and the highly polar nature of the alendronate moiety. It was necessary to have a method to bring the two components together in an aqueous environment whereby coupling would be instantaneous and essentially quantitative to facilitate puri®cation. It was decided to use a bifunctional reactive linker, d-maleimidobutyric acid N-hydroxysuccinimide ester, an agent that has been used for the conjugation of proteins.
14 This agent reacted eectively with alendronate bis-sodium salt to provide the amide 4 containing the maleimido group. PGE 2 was then transformed to its 3-mercaptopropylthioester 5 by reaction of PGE 2 , 1,3-propanedithiol and DCC. The thioester, in methanol, reacted with 4 in methanol±water to rapidly form the conjugate 6 which could be puri®ed using C18 cartridges (Scheme 2). Again, the corresponding dual-labelled compound incorporating 3 H-labelled PGE 2 and 14 C-labelled alendronate was prepared.
In vitro studies with conjugate 6. The dual-labelled conjugate 6 bound to bone powder eectively with about 80% of 3 H and 14 C bound within 5 min and tritium label was released at a more rapid rate of 10% after 24 h and 17% after 48 h in FBS. The 14 C label remained bound. This was very encouraging, suggesting 6 could be highly suitable. Unfortunately, when 6 was dosed in vivo in rats, only the 14 C label was taken up in the bones with 42.5% of 14 C label bound while only traces (0.6%) of the tritium label was taken up after 24 h. This indicated that in vivo, the thioester bond was too labile to be useful. It was therefore necessary to prepare conjugates with intermediate stability. Although the results with conjugate 3 were somewhat encouraging, there was concern that conjugates in which the 15-hydroxyl group was free might be substrates for PGE 2 dehydrogenase (an active enzyme in mammalian systems) 15 and therefore the PGE 2 moiety might be modi®ed into an inactive 15-keto form before it reached the bone or was released. It was therefore decided to redirect our eorts to the formation of conjugates where linking of bisphosphonate was eected through the 15-hydroxyl group of PGE 2 .
Synthesis and studies of conjugate bisphosphonates linked through the 15-hydroxyl group of PGE 2 Synthesis of 15-hydroxy-linked conjugates. A variety of methodologies were envisaged for achieving a linkage through the 15-hydroxyl group. All of these approaches were complicated by the need to derivatize selectively the 15-hydroxyl group and not the 11-hydroxyl group of PGE 2 and to bring the two moieties together under conditions where PGE 2 is stable and where the bisphosphonate component would have appropriate solubility and reactivity. We also wished to prepare conjugates where the coupling linkage was the only bond vulnerable to hydrolysis so that the liberation of tritium from the bone or in plasma could be unambiguously assigned to liberation of PGE 2 itself. The formation of esters appeared to be the best option but initially it was apparent that if PGE 2 were to be directly acylated by a bisphosphonate containing an acylating functionality, then the bisphosphonate moiety would have to be suitably protected and then the conjugate subsequently deprotected to yield the free bisphosphonate. Previous studies on the preparation of steroid and methotrexate bisphosphonate conjugates 16, 17 have utilized bisphosphonates protected as linear or branched alkyl (methyl, ethyl, isopropyl) esters. The deprotection of such esters following conjugation was carried out in both cases by treatment with bromotrimethylsilane at room temperature for 2 to 3 days. We con®rmed that PGE 2 was unstable under these conditions. We chose instead to prepare benzyl-protected bisphosphonates and considered that the alkylation of tetrabenzyl methylenediphosphonate (7a) was an appropriate route for synthesis of the required reagents.
We were unable to ®nd reports on the alkylation of tetrabenzylmethylene bisphosphonate and thus we undertook a study on the alkylation of 7a with electrophiles. A variety of bases, solvents and electrophiles were studied and yields were poor to moderate, often leading to a mixture of mono-and dialkylated products (8 and 9) (Table 1) . However, reactive electrophiles such as benzylbromide and 4-carbomethoxy-or 4-t-butyloxycarbonylphenylmethylbromide proceeded relatively eciently at room temperature in about 30 min. Similarly, bromomethylacetate and alkyliodides such as methyliodide could be reacted eciently using the anion prepared from 7a and sodium hydride in DMF.
With the reagents in hand, we turned our attention to the selective acylation of the C-15 hydroxy group of PGE 2 (as its t-butyldiphenylsilyl (TBDPS) ester (12)). Model studies utilizing acid chlorides such as 11 in pyridine indicated that it was possible to acylate selectively the C-15 hydroxy group of 12 (see Scheme 3). However, as had been predicted from our previous stability studies (vide supra), all attempts to deprotect the resulting conjugate 13 lead to decomposition. Attempts to hydrolyse the t-butyldiphenylsilyl ester in the corresponding tetrabenzyl bisphosphonate (8g) by treatment with tri¯uoracetic acid (TFA) lead to partial debenzylation, suggesting that this reagent was too unstable to be useful.
We next directed our eorts to the study of functionalization of bisphosphonate 8d. The desired acid chloride was prepared in good yield by hydrolysis of 8d with lithium hydroxide to give the corresponding acid (14) (70% yield) and formation of the acid chloride (15) utilizing freshly distilled oxalyl chloride in DMF. The crude acid chloride 15 was used directly for acylation of PGE 2 -TBDPS in pyridine at À20 C to 0 C to provide the desired C-15 acylated adduct 16 in 42% yield accompanied with 31% recovered PGE 2 -TBDPS. Hydrolysis of the silyl ester proceeded smoothly to 17 (94% yield) but the ®nal debenzylation proved to be very dicult and capricious. At ®rst, model reactions were used to evaluate conditions using an equimolar mixture of tetrabenzyl methylene diphosphonate (7a) and PGE 2 . Acidic conditions such as HBr (48%), DMF, water or nucleophilic debenzylation with lithium iodide in DMF resulted in decomposition of PGE 2 before complete debenzylation of the phosphonate ester. More mild conditions such as HBr (4 equiv) in DMF±water were extremely slow and unusable. A variety of hydrogenations were evaluated including Lindlar conditions; Pd/ BaSO 4 , Pd(OH) 2 in EtOAc or ethanol. All gave partial or total reduction of PGE 2 in parallel with the debenzylation. Conditions described by Noyori 18 for the reduction of acetylenes in the synthesis of PGE 2 led to no debenzylation. Gratifyingly however, transferhydrogenation with 1,4-cyclohexadiene and Pd 0 was remarkably selective. 19 For example, treatment of a 1/1 mixture of PGE 2 and bisphosphonate 8d with Pd 0 (10% on charcoal, 1 equivalent w/w of 8d) and 1,4-cyclohexadiene (10 equivalents) in ethanol at room temperature for 12 h resulted in the recovery of 91% of PGE 2 and 95% of the diphosphonic acid. This remarkable selectivity ®nds no precedent and may be speci®c to bisphosphonate benzyl esters. Application of these conditions to conjugate 16 apparently gave the desired product (18) in low to moderate yield (20±44%). Unfortunately, careful analysis of this product indicated that considerable isomerization of the double bonds in the PGE 2 moiety had taken place, presumably under the mediation of the paladium catalyst. Careful optimization of the conditions, however, utilizing 10% paladium on charcoal (15 mol%) in ethanol/ethyl acetate at 20 C followed by the addition of 1,4-cyclohexadiene (40 equiv) gave material which appeared to be about 90% pure by NMR and could be puri®ed using either C18 cartridge or C18 HPLC. With the synthesis of this conjugate in hand, a radioactive sample derived from 3 H-PGE 2 was also prepared (Scheme 4).
While this synthesis was successful, subsequent eorts to scale up the synthesis of 18 were still capricious and this led us to evaluate an alternative conjugation method wherein PGE 2 could be coupled with a bisphosphonate in its unprotected (free acid) form as the ®nal step and thus avoiding deprotection. We considered that a thiol-containing bisphosphonate should react eciently and selectively with a PGE 2 derivative containing the highly reactive 15-bromoacetyl group. The thiol-containing bisphosphonate (21) was prepared by alkylation of the anion derived from tetraisopropyl methylenediphosphonate (NaH, DMF) with 3-acetylthiopropyliodide (19) to provide the thioacetate (20) in 90% yield. Hydrolysis of the thioester and the isopropyl phosphonate esters proceeded concomitantly by re¯uxing in HCl followed by concentration to dryness under high vacuum. The resulting thiol 21 was used directly without further puri®cation. Selective esteri®cation of PGE 2 -TBDPS (12) with bromoacetylbromide in THF/pyridine at À25 C provided the mono-acylated bromoacetate (22) in 49% yield. The reaction of the bromide with a slight excess of the thiol 21 and triethylamine in dioxane/water led to the ecient coupling and concomitant desilylation of the PGE 2 ester. Puri®cation using C18 reverse-phase silica gel followed by cation exchange (Dowex 50 Na + form) gave the product conjugate (23) in 66% yield. The conjugate could be further oxidized using 32% peroxyacetic acid followed by dimethyl sul®de workup to provide the corresponding sulfoxide (24) in quantitative yield (Scheme 5). Subsequent studies on conjugate 23 indicated it had properties appropriate for optimal in vivo activity (vide infra). It was necessary to prepare an authentic sample of the bisphosphonate carboxylic acid (26) that would be liberated on hydrolysis of the conjugate for determination of its intrinsic in vivo activity. This was achieved by alkylation of 21 with the hexyl ester of bromoacetic acid to provide the corresponding ester 25 which could be separated from an unreacted bisphosphosphonate thiol and other bisphosphonate derived by-products by C18 chromatography. The product, obtained in 62% yield, was then hydrolyzed by HCl/re¯ux to provide the thioacetic acid 26 in quantitative yield (Scheme 6). Using 3 H-labelled PGE 2 , 3 Hlabelled analogues of 18, 23, 24 and 31 were prepared.
Synthesis of conjugates incorporating the two moles of PGE 2 per mole of bisphosphonate. All PGE 2 -bisphosphonate conjugates described above contain an equivalent molar amount of PGE 2 per mole of bisphosphonate. It was considered potentially advantageous if multiple molar quantities of PGE 2 could be delivered per mole of bisphosphonate. We therefore investigated the possibility of incorporating more than one equivalent of PGE 2 utilizing a polysubstituted bisphosphonate. This was achieved utilizing 1,3,5-tris(bromomethyl)-benzene (27) as a common coupling unit. Reduction of trimethyl 1,3,5-benzenetricarboxylate with borane/ dimethyl sulfate complex provided the corresponding 1,3,5-tris(hydroxymethyl)benzene in quantitative yield which was brominated with phosphorus tribromide in ether to provide the tribromide 27. The anion derived from tetraisopropyl methenediphosphonate was alkylated with the tribromide to provide the corresponding monoalkylated bisphosphonate 28 in 63% yield. Reaction of 28 with potassium thioacetate gave the bisthioacetate 29 in 70% yield. Hydrolysis of 29 with 6 N HCl proceeded to 30 in essentially quantitative yield (98%). The bromoacetate 22 (2 equiv in dioxane) was added to 30 in water/triethylamine to provide the bisalkylated bisphosphonate 31 which was puri®ed by C18 chromatography and lyophylization (52% yield) (Scheme 7). With these four conjugates now in hand, we undertook a series of in vitro and in vivo biological experiments to evaluate their potential for stimulation of bone growth.
Enzymatic hydrolysis of conjugates 18, 23, 24, and 31. The rate of release of PGE 2 from the conjugates 18, 23, 24, 31 when incubated with rat plasma was measured in two sets of experiments. In the ®rst, [
3 H]-18 was incubated with fresh rat plasma (50%) at 37 C and liberated tritium was measured by separation of unreacted 18 and liberated`PGE 2 ' using silica gel chromatography.
As can be seen in Figure 3 , a signi®cant amount of label (20%) was liberated in 2 h relative to incubations with boiled plasma controls or with pH 7.2 phosphate buffered saline (PBS) alone.
In a second set of experiments, conjugates 23 and 24 (0.1 mCi each) were compared with conjugate 31 (0.2 mCi or molar equivalent bisphosphonate) in 100% rat plasma at 37 C for up to 24 h. As can be seen in Figure  4 , both conjugates 23 and 24 released tritium at a reasonable rate with conjugate 31 releasing 51% after 24 h compared to 17.5% in a PBS control incubator and 25.4% in a boiled plasma control (Fig. 5) .
It was concluded that esterase activity in rat plasma can hydrolyze each of these conjugates at an acceptable rate. There remained some question as to the nature of the liberated tritium in these experiments. It was possible that label could be liberated by elimination of the 15-ester rather than hydrolysis. In a preliminary incubation of conjugate 18 with rat plasma, direct radioimmunoassay analysis of the released radioactive contents revealed that only $10% of radioactivity could be accounted for as PGE 2 (data not shown). We thus sought to characterize the nature of the liberated label by HPLC. [
3 H]-PGE 2 or [ 3 H]-conjugate 31 was incubated with PBS, boiled plasma or fresh rat plasma for 4 or 24 h and HPLC analysis showed that the products in each case were similar. Thus PGE 2 in PBS or boiled plasma was converted to PGA 2 while in fresh plasma PGB 2 and unidenti®ed label at the solvent front (presumed to be tritiated water due to its volatility) were observed together with unreacted PGE 2 . Conjugate 31 liberated the same products but little or no PGE 2 was observed. These results were in keeping with the liberation of PGE 2 from 31 and subsequent conversion by albumin to PGB 2 with concomitant liberation of tritium with water by exchange (Fig. 6 ). Fitzpatrick and Wynalda 20 have shown that albumin sequesters PGE 2 and accelerates dehydration and isomeration into PGB 2 (due to an alkaline microenvironment associated with the binding site). The lack of signi®cant PGE 2 observed to be liberated from 31 can be considered reasonable in that it is being slowly released in minute quantities and concomitantly decomposing to PGA 2 or PGB 2 . Clearly no elimination of the 15-ester group was taking place. were dosed intravenously in rats at 1 mg/kg and sets of rats (n=5 or 6) were sacri®ced at 6 h, 48 h and 7 days post dose and tritium levels in long bones were determined. As can be seen in Figure 8 , uptake was moderate (3±3.5%) at 6 h but release was smooth and consistent in each case with about 30±50% release over the 7 day period. Based on these results, it was decided to take conjugate 23 into a long-term (4 week) trial in ovariectomized rats to measure eects of the conjugate relative to PGE 2 .
In vivo eects of conjugate 23 in a rat model of osteoporosis. The conjugate 23 was evaluated during a 4-week study in ovariectomized (ovx) osteopenic rats for eects on bone formation at doses of 10 or 100 mg/kg iv once weekly. Controls included (i) intravenous saline vehicle, (ii) the mixture of the core bisphosphonate 26 plus PGE 2 each dosed once weekly at 5 mg/kg iv, (iii) a positive control of rats dosed daily at 6 mg/kg PGE 2 ®ve times per week subcutaneously (s.c.) and (iv) a negative control of sham-ovariectomized rats dosed s.c. with saline vehicle. The results are presented in Tables 2 and  3 . The anti-resorptive eect of 26, the core bisphosphonate, was also evaluated alone in the growing rat model (Schenk assay 21 ) in rats dosed s.c. at 0, 3 and 30 mg/kg per day for 10 days.
Eight weeks post-ovariectomy animals developed the expected osteopenia due to estrogen de®ciency. Compared to the sham-ovx group femoral bone mineral content (BMC) decreased by 14%. Tibial structural indices of bone volume (BV/TV) and trabecular number (TbN) decreased by 58% while trabecular separation increased threefold. There was also a non-signi®cant decrease in trabecular thickness. Mineralizing surface (MS/BS), mineral apposition rate (MAR), and bone formation rate (BFR/BS) were signi®cantly increased due to ovariectomy ( Table 2 ).
The group treated with 23 (10 mg) and its two relevant controls (groups: OVX-VEH, 26+PGE 2 ) were further analyzed. Both the 26 plus PGE 2 and 23 groups showed small but signi®cant increases in femoral BMC compared to the vehicle treated group (Table 3) . There were no signi®cant dierences in tibial bone volume (BV/TV) or mineral apposition rate (MAR) in either of the three groups. However, the 23 treated group did have signi®cantly increased mineralizing surface (MS/BS) of 25± 50% and bone formation rate (BFR/BS) of 33±54% compared to the other two treated groups. Treatment with 23 did produce signi®cant increases in mineralizing surface, mineral appositional rate, and bone formation rate compared to the combined 26+PGE 2 treated group alone; however, the structural indices of cancellous bone, trabecular thickness, trabecular number, and trabecular separation were not dierent (data not shown).
An apparent dose response 23 is shown in Table 3 . Both the 10 mg/kg and 100 mg/kg doses showed signi®cant increases in femoral BMC of 8% and 14%, respectively, while the 6 mg/kg/d PGE 2 treated group increased by 22% compared to vehicle. A twofold increase in mineralizing surfact (MS/BS) was seen in all treatment groups compared to vehicle. The 100 mg/kg dose group had a signi®cantly higher mineral apposition rate (MAR) and the bone formation rate (BFR/BS) was also signi®cantly increased two-to threefold compared to the vehicle treated group. Signi®cant increases BFR/BS in the 10 mg/kg and PGE 2 treated groups albeit not as great were also seen. However, there were no signi®cant dierences in tibial bone volume (BV/TV) between groups. It appears that in these animals, the major eect of PGE 2 was on cortical bone, a major contributor to total BMC. In the Schenk assay, treatment with 26, the bisphosphonate core of 23, at doses up to 30 mg/kg for 10 days did not produce signi®cant increases in femoral ash weight indicating that it is not an eective inhibitor of bone resorption (data not shown).
Conclusions
Studies on the synthesis of a variety of conjugates of the bone growth stimulating PGE 2 with bone targeting bisphosphonates have lead to the preparation of conjugates with covalent coupling via the C-1 carbonyl group and the C-15 hydroxyl group of PGE 2 . Amides at C-1 proved to be too stable and, while taken up in bone eciently, were not suciently labile to be hydrolyzed in vivo. A thio-ester conjugate proved to be too labile and was hydrolyzed rapidly in the bloodstream before it could be taken up in bone. Methods were developed to conjugate PGE 2 to bisphosphonate via the C-15 hydroxyl group. The conjugate 23 was taken up moderately well and was subsequently released at a slow but steady rate ($50% over 1 week) suggesting it could deliver PGE 2 in situ at an acceptable rate. The conjugate was very well tolerated at high doses (up to 100 mg/kg, equivalent to $50 mg/kg PGE 2 ) with $5% deposited in bone and PGE 2 liberated at a rate of about 6±7% per day or the equivalent of $200 mg PGE 2 /kg/ day at the highest dose. The bone formation stimulation of this dose was comparable or superior to PGE 2 dosed at its maximum tolerated dose of 6 mg/kg/day (5 days per week) administered subcutaneously, with respect to increase in bone mineral content, mineralizing surface, mineral apposition rate and bone formation rate. However, neither treatment overcame the cancellous bone osteopenia produced by 2 months of estrogen de®ciency. A longer treatment period or higher doses of PGE 2 possibly deliverable via the bis-conjugate 31 may translate these changes in bone formation rates into bone volume increases. Alternatively, conjugation to an active bisphosphonate could combine increased bone formation with inhibition of bone resorption. Femoral bone mineral content (BMC) increased dose dependently compared to vehicle and this eect was not due to an anti-resorptive eect of the bisphosphonate core (26). Thus as proof of concept experiments, these results support bone formation by local release of prostaglandin E 2 from a conjugate compound.
Experimental General methods
All reagents and dry solvents were obtained from commercial sources and used without further puri®cation. 1 H and 13 C NMR spectra were recorded on a Bruker ARX-400 or AMX-300 instrument. Infrared spectra were recorded on a Perkin±Elmer 681 spectrometer. Melting points were taken on a Mettler FP61 apparatus and are uncorrected. Low resolution mass spectra and elemental analyses were obtained from Oneida Research Services. High resolution mass spectra were obtained at the Biomedical Mass Spectrometry Unit, McGill University using a ZAB 2F HS instrument. PGE 2 -alendronate conjugate (3). 1,3-Dicyclohexylcarbodiimide (3.6 mg) was added to a stirred solution of PGE 2 (1a) (3.1 mg) and N-hydroxysuccinimide (3.0 mg) in dry acetonitrile (200 mL) and stirred at room temperature (25 C) until thin-layer chromatography indicated that the reaction was complete. The solvent is removed under an inert atmosphere (nitrogen) and the residue was dissolved in CH 2 Cl 2 and applied to a small column of silica gel in a pasteur pipette. The pipette was then eluted with EtOAc to aord the hydroxysuccinimide ester (1b) and a small quantity of dicyclohexylurea.
1 H NMR (CDCl 3 ): d 5.45±5.7 (2H, m, H-13,14), 5.37 (2H, m, s, H-5,6), 3.95±4.15 (2H, m, H-11,15), 2.85 (4H). A solution of this ester in 1,4-dioxane was added to a stirred solution of alendronate disodium salt (2) (ABP) (2.4 mg) in water (150 mL) and 1.0 NaOH (10 mL). After 10 min the pH of the reaction mixture was adjusted to approximately 9 with 1.0 M aqueous NaOH, and then 1 h later the pH was adjusted to 7 with 0.1 M HCl. The solution is ®ltered and the ®ltrate was concentrated to dryness. The residue was then dissolved in water and applied to a Varian Bond Elute C18 pack which was eluted with water. When the product began to elute, the solvent system on the C18 column was changed to acetonitrile/water (50/50). Evaporation of fractions containing the product aorded the target amide (3) (3.7 mg). 1 3 H-14 C-conjugate 3. The identical procedure was followed with tritiated PGE 2 and 14 C-labelled alendronate monosodium salt to produce the dual-labelled 3 (speci®c activity 7 mCi/mmol each in 3 H and 14 C).
Synthesis of PGE 2 -thioester-alendronate conjugate (6). Dicyclohexylcarbodiimide (0.2 g) was added to a stirred solution of N-(4-carboxybutyl)maleimide (0.12 g) (mp 87±89 C prepared in the same way as the procedure in Coleman et al. 22 ) in dichloromethane (10 mL) containing N-hydroxysuccinimide (0.38 g). After 2 h, the reaction mixture was poured onto a silica gel column which was eluted with EtOAc aording bifunctional reagent N-(4-maleimidobutyric acid) N-hydroxysuccinimide ester (0.086 g). 1 H NMR ((CD 3 ) 2 CO) d 6.85 (2H, s), 3.50 (2H, 5), 2.87 (4H, s), 2.72 (2H, t), 1.98 2H, dt).
A solution of the active ester (12 mg) in 1,4-dioxane (200 mL) was added to a stirred solution of alendronate (ABP) (7 mg) in water (400 mL) and 1 N sodium hydroxide (25 mL). After 15 min the solution was adjusted to pH 7 with 0.1 N HCl and then lyophilized. The resulting powder was dissolved in water and eluted through two Varian 6 mL C18`bond elute' cartridges with water, collecting the ®rst 4 mL from each cartridge. This solution was lyophilized and the resulting colorless powder contained the maleimide derivative (4) as well as N-hydroxysuccinimide and, perhaps, some unreacted ABP.
1 H NMR (D 2 O) d 6.72 (2H, s), 3.40 (2H, t), 3.01 (2H, t), 2.13 (2H, t), 1.9±1.6 (6H, m).
A solution of PGE 2 (1a) (5 mg) in CH 2 Cl 2 (500 mL) was stirred under nitrogen and treated with 1,3-propanedithiol (14 mL) and dicyclohexylcarbodiimide (8 mg). The reaction was followed by thin-layer chromatography (TLC) and when complete ($4 h) the reaction mixture was poured onto a small silica gel column in a pasteur pipette. Elution with deoxygenated EtOAc aorded the thiolester (5). This was immediately dissolved in methanol (500 mL) and added to a solution of 4 in aqueous methanol (1 mL, 1/1 v/v). The solution was allowed to stand for 15 min, then most of the methanol was evaporated and the residual aqueous solution was lyophilized. The crude product was dissolved in water and absorbed onto a Varian 6 mL C18 bond elute cartridge. This was eluted with water (9 mL), 30% MeOH/ H 2 O (6 mL), then 60% MeON/H 2 O (6 mL). The ®rst 3 mL of the 60% MeOH fraction contained all the product (6) obtained as a white powder (4.6 mg) after lyophilization. mp >260 C (dec). 13 14 C]-conjugate 6. The identical procedure as described above was followed with tritiated PGE 2 and 14 C labelled ABP monosodium salt to produce the dual labelled conjugate 6 (speci®c activity 4.48 mCi/mmol tritium and 5.76 mCi/nM 14 C).
Tribenzyl orthoformate. Benzyl alcohol (390 mL, 3.6 mol) was added to a solution of triethyl orthoformate (150 mL, 0.9 mol) in benzene (350 mL) at room temperature. Tri¯uoroacetic acid (6.8 mL, 0.09 mol) was then added at room temperature and the mixture was slowly distilled under reduced pressure (35 C, 20 mm Hg) until the volatiles (EtOH, C 6 H 6 , TFA) had distilled. Excess benzyl alcohol was distilled (75 C, 0.1 mm Hg) and the residue consisted mainly of tribenzyl orthoformate which could be distilled (170±185 C, 0.1 mm Hg) although it could be used crude in the next step. 1 
Alkylation of tetrabenzyl methylenediphosphonate (7a)
Typical procedure. Sodium hydride (60%) (291 mg, 7.3 mmol) was added portionwise to a solution of tetrabenzyl methylenediphosphonate (7a) (3.0 g, 5.5 mmol) in DMF (10.0 mL) at room temperature. The mixture was stirred at room temperature for 60 min and a solution of methyl p-bromomethylbenzoate (1.9 g, 8.4 mmol) in THF (2.0 mL) was added. The mixture was stirred at room temperature for 30 min and a solution of saturated ammonium chloride (15 mL), water (100 mL), and a (1/1) mixture of ether/hexanes (100 mL) were added. The separated aqueous layer was extracted with a (1/1) mixture of ether/hexanes (3Â100 mL) and the combined organic layers were washed (brine), dried (MgSO 4 anh.), ®ltered and evaporated. Flash-chromatography (EtOAc/hexanes, 1/1) of the residue gave monoalkylated product 8d (1.8 g, 47%) along with dialkylated product 9d (670 mg, 14%). Spectral data for compounds 8 and 9 are given below. Tetraisopropyl 2-carboxyethane-1,1-diphosphonate (10). Tri¯uoroacetic acid (5.5 mL) was added to t-butyl ester 8i (1.1 g, 2.4 mmol) at room temperature and the mixture was stirred for 60 s at room temperature and evaporated under reduced pressure. Flash-chromatography (EtOH/EtOAc, 1/9) of the residue gave carboxylic acid 10 (802 mg, 83% Acid chloride (11) . Thionyl chloride (182 mL, 2.5 mmol) was added to a solution of carboxylic acid 10 (201 mg, 0.5 mmol) in dichloromethane (2.5 mL) at room temperature. The mixture was heated to re¯ux for 3 h, cooled and evaporated under reduced pressure to give 200 mg (95%) of acid chloride 11 used directly in the next step. IR (neat) 1800 cm À1 .
PGE 2 -t-butyl-diphenylsilyl ester (PGE 2 TBDPS) (12).
To a solution of PGE 2 (352.5 mg, 1 mmol) in CH 2 Cl 2 (5 mL) at 0 C was added t-butyldiphenylsilylchloride (275 mL, 1.1 mmol) and triethylamine (278 mL, 2.0 mmol) consecutively via microsyringe. The mixture was stirred at 0 C for 2 h, then the solvent was evaporated and the residue puri®ed by¯ash chromatography on silica gel eluting with ethyl acetate to provide PGE 2 -TBDPS ester (12) (592 mg, 100%) . 1 (13) . A solution of PGE 2 -TBDPS ester (61 mg, 0.1 mmol) in pyridine (150 mL) was added to a mixture of acid chloride 9 (110 mg, 0.25 mmol) and pyridine (150 mL) at room temperature. The mixture was stirred at room temperature for 3 h and a solution of saturated ammonium chloride (2 mL), water (10 mL), and ethyl acetate (20 mL) were added. The separated aqueous layer was extracted with ethyl acetate (3Â20 mL) and the combined organic layers were washed (brine), dried (MgSO 4 anh.), ®ltered and evaporated. Flash-chromatography (EtOAc (100%) then EtOH/EtOAc, 1/9) of the residue gave PGE 2 Tetrabenzyl 2-(4-carboxyphenyl)ethane-1,1-diphosphonate (14) . A solution of lithium hydroxide (84 mg, 2.0 mmol) in water (1.0 mL) was added to a solution of methyl ester 8d (455 mg, 0.6 mmol) in 1,4-dioxane (1.0 mL) at room temperature. The mixture was stirred at room temperature for 5 h and a 1 N solution of HCl (10 mL) was added. Dioxane was evaporated under reduced pressure and the mixture was diluted with EtOAc (20 mL). The separated aqueous layer was extracted with EtOAc (3Â50 mL) and the combined organic layers were washed (brine), dried (MgSO 4 anh.), ®ltered and evaporated. Flash-chromatography (HOAc/ EtOH/EtOAc, 0.1/1/9) of the residue gave carboxylic acid 14 (210 mg, 48%). CDCl 3 ): d 9.65 (1H,  br. s), 7.98 (2H, d, J=8.1 Hz), 7.26 (20H, s) . Compound 15 was dissolved in dichloromethane (100 mL), cooled to À20 C and pyridine 50 mL was added followed by PGE 2 -TBDPS in pyridine (350 mL) and dichloromethane (100 mL). After stirring 10 min at À10 C and 0.5 h at 0 C. A solution of saturated ammonium chloride was added and the mixture was extracted with EtOAc acetate (3Â5 mL). The organic extracts were washed with brine, dried over magnesium sulfate and evaporated to dryness. The residue was puri®ed by HPLC (ZORBAX, 21±5Â25 cm, 20 mL/min EtOAc: hexane, (80/20) as eluant). The ®rst fraction corresponded to the C-11 regioisomer (16b) (66.4 mg; 18%). The second fraction was the desired C-15 regioisomer 16a (156.4 mg, 42%). Ethyl acetate elution provided the bis-acylated product (20 mg C water bath. To the solution was added Pd/C (5% Pd content, 5.7 mg, 0.036 mmol) followed by 1,4-cyclohexadiene (136 mL, 1.44 mmoL) and the resultant mixture was stirred at room temperature for 4.5 h and transferred to a 1.5 mL plastic Eppendorf vial and centrifuged. The supernatant was separated and the residue rinsed twice with ethanol (1 mL). The supernatants were combined, neutralized with 0.5 N ammonium acetate (144 mL, 0.072 mmol) and concentrated. The crude product ($90% pure by 1 H NMR) could be puri®ed in two ways: (1) by C18 mini-columns (6 mL Varian Bond Elute) using water (5 mL), 30% MeOH/water (5 mL), 60% MeOH/water (5 mL) and MeOH (5 mL). The desired product eluted with the 30% MeOH/water fraction. The fraction was lyophilized to aord the compound 18 (21 mg, 76%); as a light-yellow¯uy powder. (2) by HPLC using Waters PrepPak mbondapak 1 C18 column (25Â100 mm, 10 mL/min, gradient composition: 0.5 N NH 4 OAc/ CH 3 CN=90/10 to 70/30 in 10 min and 70/30 for 10 min, UV detection: 254 nM). The fractions thus obtained were lyophilized to give the desired product, 18. Preparation of 4-mercaptobutane-1,1-diphosphonic acid (21) 3-acetylthiopropyliodide (19). To a solution of 1,3-diiodopropane (10 g, 33.8 mmol) in 10 mL of anhydrous DMF at 0 C under nitrogen was added, via a cannula over 15 min, a solution of potassium thioacetate (1.3 g, 11.3 mmol) in 5 mL of DMF and the mixture was stirred at 0 C for 0.5 h, quenched with water (20 mL) and extracted with ether (3Â20 mL). The extracts were combined, washed with brine and dried over MgSO 4 , ®ltered and concentrated. The residue was puri®ed bȳ ash chromatography (silica gel, EtOAc/hexane, 5/95± 10/90) to yield iodide 19 (2.5 g, 90%) as a light-yellow oil. IR (neat) 2960, 2920, 1689, 1418, 1350, 1210, 1130 cm À1 ; 1 H NMR (CDCl 3 ) d 2.00 (2H, m), 2.26 (3H, s), 2.87 (2H, t, J=7 Hz), 3.13 (2H, t, J=6.9 Hz); 13 C NMR (CDCl 3 ) d 4.35, 29.70, 30.63, 32.97, 195 .09.
H NMR (
Tetraisopropyl 4-acetylthiobutane-1,1-diphosphonate (20) . To a solution of tetraisopropyl methylenediphosphonate (9.35 g, 27 mmol) in anhydrous DMF (30 mL) was added NaH (0.96 g, 32 mmol) portionwise and the resulting suspension was stirred at room temperature for 1 h. To the above solution was then introduced dropwise a solution of iodide 4 in DMF (7 mL) and the mixture was stirred at room temperature for 2 h, quenched with saturated aqueous ammonium chloride and extracted with EtOAc (3Â60 mL). The extracts were combined, washed with brine and dried over Na 2 SO 4 , ®ltered and concentrated in vacuo. The residue was subjected to KughroÈ r distillation to remove the unreacted starting material. The residue of the distillation was puri®ed by¯ash chromatography (silica gel, EtOH/ CH 2 Cl 2 , 0/100±3/97) to furnish bisphosphonate 20 15-Bromoacetyl PGE 2 -TBDPS ester (22) . To a solution of PGE 2 -TBDPS (3.3 g, 5.58 mmol) in anhydrous THF (9 mL) at À25 C was added pyridine (0.54 mL, 6.7 mmol) and bromoacetylbromide (0.54 mL, 6.14 mmol) and the suspension was stirred 10 min at À25 to À20 C. The mixture was quenched with saturated aqueous ammonium chloride, warmed to room temperature and extracted with EtOAc. The organic layer was washed with brine, dried over Na 2 SO 4 and concentrated in vacuo. The crude product was puri®ed by¯ash chromatography (silica gel, EtOAc/hexane, 10/90±40/60) to yield the desired compound 22 (1.93 g, 49%) as a colorless oil. IR (neat) 3460, 2950, 2928, 2855, 1725, 1460 The residue was puri®ed by¯ash chromatography (silica gel C-18, MeOH/water, 0/100±60/40). The desired product came out in the 30% MeOH/water fractions which were ®ltered on a cation exchange (DOWEX 50 Na + form, 35 g). The ®ltrate was lyophilized to give the desired conjugate 23 (2.8 g, 66%) as a white sticky solid. 24 . To a solution of conjugate 23 (10 mg, 0.0145 mmol) in 1 mL of MeOH was added at room temperature a 32% peracetic acid (3.37 mL, 0.016 mmol) solution and the mixture was stirred for 10 min. Dimethyl sul®de was then added and after 5 min the solvents of the reaction were removed to give sulfoxide 24 (10.2 mg, 100%). Tetraisopropyl 2-(3,5-bis(bromomethyl)phenyl)ethane-1,1-diphosphonate (28). NaH (0.216 g, 5.4 mmol) was added at room temperature to a solution of tetraisopropyl methylenediphosphonate (1.77 g, 5.14 mmol) in 7 mL of anhydrous DMF and the suspension was stirred for 30 min under nitrogen. The resulting solution was transferred via a cannula to a solution of 1,3,5-tris(bromomethyl)benzene 27 (3.658, 10.2 nmol) in 8 mL of anhydrous DMF. The mixture was stirred for 1.25 h, quenched with a saturated solution of ammonium chloride and extracted with EtOAc (twice). The extracts were combined, washed with brine and dried over Na 2 Bis-(PGE 2 )-bisphosphonate conjugate (31). To a solution of bromide 22 (103 mg, 0.144 mmol) in dioxane (1 mL) at room temperature and under nitrogen was added dropwise via a cannula a solution of thiol 30 (25.8 mg, 0.072 mmol) and triethylamine (50 mL, 0.36 mmol) in water (0.5 mL) and the solution was stirred at room temperature for 2 h and concentrated. The residue was partitioned between EtOAc and water. The aqueous layer was washed twice with EtOAc and ®ltered on a cation exchange (DOWEX 50 Na + form). The ®ltrate was concentrated and the residue was puri®ed by¯ash chromatography (silica gel C18, MeOH/water, 0/100± 60/40). The desired product came eluted in the 30% and 60% methanol/water fractions which after lyophilization gave the desired conjugate 31 (44 mg, 52%) as a light-yellow sticky solid. 1 H) was placed in 1 mL 100% fetal bovine serum to yield a ®nal concentration of 3.5 mM. 200 mM of this solution was incubated with 10 mg bone powder for 1, 2, 3 and 5 min with vigorous shaking. The mixture was centrifuged (20 s), 125 mL aliquot was taken from each sample and counted in 10 mL Atomlight in an LKB liquid scintillation counter, 125 mL of the radioactive sample was also counted at 0 time. The uptake of radioactivity into the bone powder was calculated by subtracting the dpms in the medium counted at the times indicated above from dpms at 0 time and this number was divided by the dpms at 0 time. The data demonstrated that about 76% of the 14 C-moiety and 53% of the 3 H-moiety were taken up by bone particles within 1 min. In a separate experiment, 77% 3 H-ABP was taken up by bone in 1 min.
In vitro dissociation of conjugate 3 from human bone powder. (20 s) , 100 mL aliquot was taken and counted in Atomlight in an LKB liquid scintillation counter. The rest of the 900 mL solution was withdrawn, the bone powder was washed once with 1 mL phosphate buered saline, 1 mL fresh fetal bovine serum was added and incubated with the bone powder for 15, 24, 39, 48, 59, 79 and 103 h in a shaking bath at 37 C. 100 mL aliquots were withdrawn at these times and counted in 10 mL Atomlight in an LKB liquid scintillation counter. The release of radioactivity from the human bone powder into the medium was calculated as follows: dpms from 100 mL of the [ 3 H]-PGE 2 / [ 14 C]-ABP at 5 min were subtracted from dpms at 0 time. The resulting dpms re¯ect radioactivity taken up by bone powder. The dpms obtained by counting 100 mL aliquots at each time point were then divided by the dpms taken up by bone. 13% of the 3 H-moiety was released into the medium at 15 h and by 103 h 32.9% of the radioactivity was released into the medium. About 5% of the 3H moiety was released per day whereas the dpms of 14 C-moiety in the medium were not signi®cantly changed during this time frame.
In vivo uptake and release of dual-labelled conjugate 3 and [
3 H]-alendronate in rat tibiae and femora 14 C]-ABP (dual-labelled conjugate 3), which was administered to seven rats, corresponds to 0.24 mg/kg. After 1, 14 or 28 days, animals were sacri®ced by CO 2 and the tibiae and femora were dissected, weighed and then stored at 20 C. The amount of radioactivity incorporated into the bone was determined by incineration in a Packard combuster after ®rst air drying the bone for 3 days at ambient temperature. The percent of the compound retained in the skeleton at each time point was calculated on the basis of the radioactivity, converted to nmoles/gm bone on the assumption that the skeleton represents 8% of the body weight. The skeletal retention was expressed as percent administered dose.
Eect of conjugate 3 on bone resorption estimated by urinary excretion of lysylpyridinoline in the rat Four-week old Sprague±Dawley female rats were injected i.v. via the tail vein with equimolar weekly doses of alendronate (1 mg/kg, n=5), conjugate 3 (2.4 mg/kg, n=5), PGE 2 (1.4 mg/kg, n=5), or saline (n=4) each. Filtered urine was collected after 12 and 26 days by housing individual rats in metabolic cages and providing them with food and water ad libitum. The overnight collections of urine were centrifuged at 1000Âg for 10 min to remove any particles and the supernatant¯uid was stored at À80 C until analysis. Lysylpyridinoline (LP) was extracted from duplicate 1 mL aliquots by acid hydrolysis and subsequent low pressure CF-1 chromatography according to the method of Beardsworth.
23 LP was further resolved by high pressure liquid chromatography according to the method of Uebelhart 24 and quantitated by comparison with an external standard. Urinary creatinine was measured using the picric acid colorimetric assay (Pharmacia Diagnostics Inc., Fair®eld, NJ). Final results were expressed as pmoles LP per mmole creatinine.
In vitro binding and dissociation of conjugate 6 to human bone powder Incubation of dual-labelled conjugate 6 (speci®c activity 3 H 4.48 mCi/nM) and 14 C 5.76 mCi/nM in a manner similar to studies described for conjugate 3 led to 79% uptake of tritium and 81% uptake of 14 C label. After uptake, incubation with fetal bovine serum, as previously described for conjugate 3, led to 10% release of 3 H at 24 h and 17% release of 3 H at 48 h compared with 2% and 3% of 13 C label at the same time points.
In vivo uptake and release of dual-labelled conjugate 6 in rat tibiae and femora
Dual-labelled conjugate 6 (30.8 nmoles/rat; 0.14 mCi 3 H, 0.18 mCi 14 C) was administered in a manner as described for conjugate 3. Analysis of tibiae and femora indicated 42.4% uptake of 13 C after 1 day and 40.2% after 14 days. Levels of 3 H observed were 0.6% after 1 day and 0.3% after 14 days.
Hydrolysis of conjugate 18 in rat plasma
In a typical experiment, a stock solution of conjugate 18 (50 mL, 18 mg, 0.02 mCi) was added to 1 mL solution of rat plasma (diluted to 50% with PBS) at 37 C and the mixture was vortexed and incubated at 37 C for 15 min, 1, 2 and 4 h. At each time interval, 200 mL of the incubate was pipetted into a 1 mL Eppendorf vial and diluted with 200 mL acetonitrile. The suspension was centrifuged at 14K rpm for 3 min and 200 mL of the supernatant was pipetted into the silica gel column (preconditioned with either toluene or isopropyl alcohol). The column was then eluted with 2 mL methanol and the collect solution was counted on a Beckmann 2000 b-sintillation counter. The radioactivity obtained divided by the original loading represented the percentage of hydrolysis. The same experiments were carried out using 50% boiled plasma (diluted with PBS) as control and PBS as control.
Hydrolysis of conjugates 23, 24 and 31 in rat plasma
In a set of experiments essentially as described above but utilizing 100% rat plasma 3 H-labelled conjugates 23 (36 mg, 0.1 mCi), 24 (38 mg, 0.1 mCi) and 31 (62 mg, 0.2 mCi) were incubated in fresh heperinized rat plasma at 37 C. Aliquots (100 mL) were worked up as before and the eluted 3 H-label counted.
Characterization of 3 H liberated on hydrolysis of conjugate 31
A stock solution of 0.4 mCi conjugate 31 or [ 3 H]-PGE 2 (0.4 mCi) was incubated in either fresh rat plasma, boiled plasma or PBS (mL) at 37 C. After 4 h or 24 h, 100 mL aliquots were removed, diluted with acetonitrile (100 mL), vortexed and centrifuged. 100 mL of supernatant was separated by HPLC (C-18, 0.5% HOAc in water, 66%: acetonitrile 33%, 1 mL/min) with euent monitored by an on-line scintillation detector and UV detector. No radioactivity was eluted under these conditions when 0.2 mCi, conjugate 31 (62 mg) was applied. (It was necessary to mix 0.4 mg of unlabelled 31 with 0.1 mCi labelled 31 to recover 0.05 mCi from the HPLC.) Radioactive peaks were identi®ed by coelution with authentic [
3 H]-PGE 2 and cold PGA 2 . An authentic sample of PGB 2 was prepared by incubating PGE 2 (2.4 mg) with 1 mL rat plasma at 37 C for 24 h. The sample, puri®ed by HPLC, had appropriate 1 H NMR, UV and MS. To identify radioactive peaks eluting at the solvent front with incubation of conjugate 31 for 24 h in fresh rat plasma, the fraction was collected and distilled. The collected distillate had 60% of the initial counts.
Binding of conjugates [
3 H]-23 and [ 3 H]-31 to human bone powder and release of label Studies were carried out essentially as described previously for conjugate 3 using 0.1 mCi conjugate per 10 mg bone powder.
In vivo uptake and release of In vivo studies were carried out essentially as previously described for conjugate 3 with Sprague±Dawley rats dosed at 1 mg/kg, $0.3 mCi/rat. In vivo assay of conjugate 23 in a rat model of osteoporosis. Brie¯y, three month old Sprague±Dawley rats were ovariectomized and were kept for 8 weeks prior to the start of treatment to allow the development of osteopenia. Treatment groups received 10 or 100 mg/kg 23, iv (see Table below ). Control groups included: an ovariectomized vehicle treated group, a sham operated nonovariectomized group, group 4 receiving equimolar doses of non-conjugated bisphosphonate (26) plus PGE 2 , and group 5 PGE 2 alone. All animals were treated for 4 weeks. Animals received the¯uorescent bone label calcein (20 mg/kg ip) 14 and 4 days prior to sacri®ce. Femora, tibiae and vertebrae were removed and ®xed in 70% EtOH. The femoral bone mineral content (BMC) was measured using a HOLOGIC QDR 4500A X-ray densitometer. Femoral length was also measured. Tibiae were processed without decalci®cation through increasing concentrations of EtOH and embedded in methylmethacrylate using a Hypercenter XP tissue processor. Five micron thick Masson's Trichrome stained sections were used to measure the following static histomorphometric variables of cancellous bone structure. Bone volume/tissue volume (BV/TV, %), trabecular number (Tb.N, #/mm), trabecular thickness (TbTh., mm), trabecular separation (TbSp., mm) were measured or calculated directly from primary measurements of tissue area, trabecular bone area, and trabecular bone perimeter. Ten-micron thick sections were coverslipped unstained for dynamic¯uorochrome label measurements. Viewed under epi¯uorescence the length of calcein labeled bone surfaces and the interlabel distances were measured. The mineralizing surface (MS/BS, %) was calculated as one-half the length of single labeled surface plus the length of the double labeled surface expressed as a percentage of total bone surface. This measures the relative amount of bone surface undergoing formation. The mineral apposition rate (MAR, mm/day) was calculated as the mean of equidistant points between the ®rst and second label divided by the labeling interval (14 days) and estimates the cell based formation rate. Bone formation rate surface referent (BFR, BS, mm 3 /mm 2 /year) or the estimated 3D volume of bone formed per measured 2-D bone area was calculated as the product of mineral apposition rate (MAR) and the mineralizing surface (MS) expressed per year.
The anti-resorptive eect of 26, the bisphosphonate core of 23 was also evaluated using the growing rat model (Schenk Assay) . Using this model rats were treated sc for ten days at 0, 3, or 30 mg/kg. After necropsy, femora are measured for length and incinerated at 700 C for 24 h. Inhibition of bone resorption in long bones (femur) of growing rats results in increased bone mineral content measured as femoral ash weight corrected for length (mg/mm).
Statistical analysis was done using the Statview (Macintosh) package. Dierences between two groups were tested using Students-t test. With three or more groups, dierences were tested using one-way analysis of variance (ANOVA). If signi®cance was found, the dierences in group means were tested using the Fisher PLSD with a P<0.05 considered signi®cant.
